Research programme: superoxide dismutase 1 target therapeutics - Thera Neuropharma

Drug Profile

Research programme: superoxide dismutase 1 target therapeutics - Thera Neuropharma

Alternative Names: RNA interference-based therapeutics - Thera Neuropharma; sd-rxRNA® based therapeutics - Thera Neuropharma; SOD1 targeting sd-rxRNA therapeutics - Thera Neuropharma; THN 1

Latest Information Update: 11 Oct 2016

Price : $50

At a glance

  • Originator Thera Neuropharma
  • Developer RXi Pharmaceuticals; Thera Neuropharma
  • Class Small interfering RNA; Small molecules
  • Mechanism of Action RNA interference; Superoxide dismutase modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Amyotrophic lateral sclerosis

Most Recent Events

  • 03 May 2016 Preclinical trials in Amyotrophic lateral sclerosis in USA (Parenteral)
  • 03 May 2016 Thera Neuropharma and RXi Pharmaceuticals have jointly files for patent protection for the management of neurodegenerative diseases associated with SOD1 in USA
  • 03 May 2016 Thera Neuropharma in-licenses self-delivering RNAi (sd-rxRNA®) platform targeting SOD1 technology from RXi Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top